Insmed (NASDAQ:INSM) Upgraded by Roth Mkm to Strong-Buy Rating

Insmed (NASDAQ:INSM) was upgraded by stock analysts at Roth Mkm to a “strong-buy” rating in a report issued on Friday,Zacks.com reports.

A number of other analysts have also recently commented on INSM. The Goldman Sachs Group increased their price target on shares of Insmed from $225.00 to $258.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Wells Fargo & Company set a $195.00 target price on shares of Insmed in a research note on Thursday, December 18th. Truist Financial set a $205.00 price target on Insmed in a report on Monday, January 12th. Wolfe Research set a $167.00 price objective on Insmed and gave the company an “outperform” rating in a research note on Thursday, December 18th. Finally, Bank of America raised their price objective on Insmed from $142.00 to $187.00 and gave the company a “buy” rating in a research report on Monday, October 27th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $204.68.

Insmed Stock Down 2.6%

INSM stock opened at $156.21 on Friday. The company has a quick ratio of 4.34, a current ratio of 4.63 and a debt-to-equity ratio of 0.59. The business has a 50 day moving average price of $184.40 and a two-hundred day moving average price of $156.10. The company has a market cap of $33.31 billion, a price-to-earnings ratio of -25.24 and a beta of 1.08. Insmed has a twelve month low of $60.40 and a twelve month high of $212.75.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The company had revenue of $142.34 million for the quarter, compared to the consensus estimate of $114.33 million. During the same quarter in the prior year, the company earned ($1.27) EPS. The company’s revenue for the quarter was up 52.4% on a year-over-year basis. Analysts anticipate that Insmed will post -4.56 EPS for the current fiscal year.

Insider Activity

In other news, CFO Sara Bonstein sold 1,447 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $174.17, for a total value of $252,023.99. Following the completion of the transaction, the chief financial officer directly owned 80,506 shares in the company, valued at approximately $14,021,730.02. The trade was a 1.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO William Lewis sold 10,699 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $158.93, for a total transaction of $1,700,392.07. Following the sale, the chief executive officer directly owned 306,891 shares of the company’s stock, valued at approximately $48,774,186.63. This trade represents a 3.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 296,799 shares of company stock worth $54,296,286. 3.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. CIBC Private Wealth Group LLC boosted its holdings in shares of Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 53 shares in the last quarter. Kingsview Wealth Management LLC lifted its position in shares of Insmed by 2.7% during the 3rd quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock worth $334,000 after buying an additional 60 shares during the last quarter. Choreo LLC boosted its stake in Insmed by 2.9% in the third quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock valued at $334,000 after buying an additional 65 shares in the last quarter. ORG Partners LLC grew its position in Insmed by 12.7% in the fourth quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 74 shares during the last quarter. Finally, Spire Wealth Management raised its stake in Insmed by 11.5% during the third quarter. Spire Wealth Management now owns 777 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 80 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.